No abstract

Although tolerability was acceptable in RCC patients with previously untreated BM, sunitinib has limited efficacy in this setting.

The efficacy endpoint was not reached, and BRN-01 administration was not demonstrated as an efficient treatment to alleviate HF symptoms due to adjuvant ET in breast cancer patients. However, the study drug administration led to decreased HFS with a positive impact on QoL. Without any recommended treatment to treat or alleviate the HF-related disabling symptoms, Actheane® could be a promising option, providing an interesting support for better adherence to ET, thereby reducing the risk of recurrence with a good tolerance profile.

Funding: Pfizer, Centre Léon Bérard. Centre Léon Bérard, sponsor of the study, was responsible for trial conception and coordination, data analysis, writing of the report. Pfizer provided the study drug axitinib and funding to Centre Léon Bérard to conduct the study. Pfizer had no role in study design, data collection, data analysis, data interpretation, or writing of the report.